Showing: 11 - 20 of 37 RESULTS
News

Welcome to the Tzelepis Group

We are delighted that Dr Konstantinos Tzelepis has moved into the Milner Centre for Pathway Analysis as a new Academic in Residence. He brings significant expertise in the identification and characterisation of novel therapeutic targets using a wide range of applied functional genetics including sophisticated CRISPR-Cas9 screening platforms, which will be vital as we expand …

News

A look inside the institute

[et_pb_section fb_built=”1″ _builder_version=”4.5.3″ custom_margin=”||0px||false|false” custom_padding=”||0px||false|false”][et_pb_row _builder_version=”3.25″ background_size=”initial” background_position=”top_left” background_repeat=”repeat”][et_pb_column type=”4_4″ _builder_version=”3.25″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_text _builder_version=”4.5.3″ background_size=”initial” background_position=”top_left” background_repeat=”repeat”] For the past four years, the Milner Therapeutics Institute has been incubating in the Gurdon Institute – home to the research lab of our Director Tony Kouzarides. This provided essential support as the Milner team was growing and …

News

Launch of the Milner Therapeutics Institute

This month, we celebrated the launch of the Milner Therapeutics Institute in the Jeffrey Cheah Biomedical Centre. Key academics and consortium members gathered in our brand new auditorium. Our Director, Tony Kouzarides, gave the vision of the Milner Therapeutics Institute and lead scientists presented work from the different units within our new building, namely the …

News

Welcome to Cambridge Centre for Proteomics

A warm welcome to the team of Kathryn Lilley at the Cambridge Centre for Proteomics (CCP), who are moving into the Milner Therapeutics Institute this week! The group have just returned from the Human Proteome Organisation (HUPO) meeting in Australia, where Kathryn Lilley presented a plenary talk and two group members received prizes. Dr Eneko …

News

First pre-competitive project initiated

A key goal of the Milner Therapeutics Consortium is to enable collaborations between Cambridge academics and our Consortium companies using forward-thinking pre-competitive models. We can now announce that the first such project has been established with Ludovic Vallier at the Wellcome MRC Cambridge Stem Cell Institute, focused on the identification of new therapeutics for liver …

News

New University Enterprise Zone announced

The Milner Therapeutics Institute will form part of a University Enterprise Zone, created through a new government initiative announced today by Universities Minister Chris Skidmore. Research England, part of UK Research and Innovation, today announced 20 new University Enterprise Zones (UEZs) aimed at helping universities stimulate growth in their local economies, providing vital support for …

News

Welcome to Pathania group

We are delighted to welcome the group of Manav Pathania (Dept Oncology), who moved into the Milner Institute this month. The Pathania group have a central focus on developing new mouse models for children’s brain tumours, to better understand the diverse genetic basis of different brain tumour types. By applying CRISPR technology to test genetic …

News

Renewal of Milner Therapeutics Consortium

We are delighted to announce that the Milner Therapeutics Consortium has been renewed until 2024. The Consortium includes 7 pharma companies (Astex, AstraZeneca, Ferring, GlaxoSmithKline, J & J Innovation, Pfizer, Shionogi) who are committed to collaboration and research investment in Cambridge academic institutes. “The renewal of this Consortium is a fantastic opportunity for the Milner …